Clinical and microbiological response of pyelonephritis caused by resistant Klebsiella to colistin alone and the combination of colistin and meropenem

Comparing clinical and microbiologic response include Colistin alone and Colistin with Meropenem for treating pyelonephritis due to Klebsiella in patients hospitalized in Alzahra hospital during 2025

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221108056446N22

Enrollment

Registered

2025-12-31

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyelonephritis caused by resistant Klebsiella. Salmonella pyelonephritis

Interventions

Intervention 1: Intervention group: Treatment with colistin will be started for the patient at a dose of 9 MIU initially and then 4.5 MIU every 12 hours, with the duration of antibiotic treatment bein

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pyelonephritis caused by resistant Klebsiella pneumoniae bacteria Patient consent to participate in the study

Exclusion criteria

Exclusion criteria: The patient is not pregnant

Design outcomes

Primary

Measure	Time frame
Antibiotic therapy. Timepoint: 48 to 72 hours after starting antibiotics. Method of measurement: Blood culture and sending urine sample to the laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbasali Torfeh

Esfahan University of Medical Sciences

Torfeh_a@med.mui.ac.ir+98 913 118 7688

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026